CML
Article
Better clinical outcomes with adjuvant IFN therapy vs. adjuvant vaccine in TKI-treated patients with CML-CP
Article
Statins enhance molecular response rates in imatinib-treated patients with CML-CP
Article
Identification of mutations by ultra-deep sequencing may help predict nilotinib response in CML-CP patients
Article
Routine monitoring of imatinib plasma levels may help decide clinical course in CML
Article
Suboptimal adherence to oral anticancer medication in CML patients
Article
Cardiovascular risk stratification feasible in CML patients treated with TKI
Article
No margin for nonadherence in CML patients receiving imatinib
Latest News
New trials in leukemia: Could your patient benefit?
Late-phase trials are opening up for leukemia patients aged 1-65 years.